COIOSDeep risk insights through multi-disciplinary research across the globe
Large institutional buildings surrounded by lush green trees
Item refines Peer-reviewed Added

Liraglutide's benefit in US veterans may be larger than the LEADER trial found

Reweighting the LEADER trial onto US veterans with diabetes gave a three-year reduction in major cardiovascular events of 4.6% against 1.6%, a difference within statistical uncertainty.

The authors reweighted the LEADER placebo-controlled trial of liraglutide onto Veterans Affairs cohorts with type 2 diabetes, balancing baseline characteristics between trial and veterans. The three-year reduction in major cardiovascular events was 4.6% in the reweighted veterans against 1.6% in the trial itself. All-cause mortality moved the same way, 2.9% against 0.9%, although both differences remain within the uncertainty around the trial's estimates.

Why it is interesting: Shows how far a GLP-1 trial's effect moves when carried to a higher-risk population.

Source
American Journal of Epidemiology, 22 September 2026
Paper
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial
Authors
Josey K, Liu W, Warsavage T, Medici M, Kvist K, Derington CG et al.
DOI
10.1093/aje/kwag236
Type
Peer-reviewed article
Design
Transportability analysis reweighting the LEADER randomised trial onto US Veterans Affairs cohorts with type 2 diabetes, using augmented inverse probability weighting and approximate balancing weights
Verdict
Refines prior evidence
Driver
Obesity, diabetes and GLP-1
Free full text
Free copy in a repository (author's accepted manuscript)

Other drivers in Health today